U.S. Oil and Gas Stock News

NasdaqGS:KRT
NasdaqGS:KRTTrade Distributors

Unveiling US Undiscovered Gems in February 2026

As February 2026 begins, U.S. stock indexes have shown a strong start to the month, with key indices like the Dow Jones and S&P 500 climbing significantly, reflecting positive market sentiment despite recent economic uncertainties such as delayed jobs data due to a government shutdown. In this dynamic environment, identifying promising small-cap stocks requires careful consideration of factors like market resilience and potential for growth amidst broader economic shifts.
NYSE:DDS
NYSE:DDSMultiline Retail

3 Reliable Dividend Stocks To Consider Yielding Up To 4.8%

As February begins, major U.S. stock indexes have shown strong performance, with the Dow Jones Industrial Average climbing by 515 points and the S&P 500 nearing a record high. In this dynamic market environment, dividend stocks can offer stability and income potential, making them an attractive option for investors seeking reliable returns amidst fluctuating market conditions.
NYSE:ESI
NYSE:ESIChemicals

Element Solutions Micromax Deal Reshapes Growth Drivers And Valuation Case

Element Solutions (NYSE:ESI) has completed its acquisition of Micromax, expanding its specialty chemicals portfolio for advanced electronics applications. The company has amended its credit facilities, adding new term loans and increasing revolving credit capacity to support the transaction and future initiatives. Element Solutions, a specialty chemicals supplier to the electronics and industrial markets, is taking a bigger role in the tech hardware supply chain with the Micromax deal. The...
NasdaqGS:NXPI
NasdaqGS:NXPISemiconductor

NXP Semiconductors (NXPI) Margin Decline Challenges Bullish Earnings Growth Narratives

NXP Semiconductors (NXPI) just wrapped up FY 2025 with Q4 revenue of US$3.3b and basic EPS of US$1.80, anchored by net income of US$455m, setting the stage for how investors read the year as a whole. The company has seen quarterly revenue move from US$3.1b in Q4 2024 to US$3.3b in Q4 2025, alongside quarterly EPS shifting from US$1.95 to US$1.80, which feeds into trailing twelve month EPS of US$8.00 on revenue of US$12.3b. With trailing net income of US$2.0b and a reported net margin that has...
OTCPK:SGMO
OTCPK:SGMOBiotechs

What Sangamo Therapeutics (SGMO)'s Fabry Gene Therapy Progress And Equity Raise Means For Shareholders

Sangamo Therapeutics recently reported detailed Phase 1/2 STAAR study results for its Fabry disease gene therapy, isaralgagene civaparvovec, and confirmed a rolling Biologics License Application submission to the FDA under the Accelerated Approval pathway, supported by kidney function as an intermediate clinical endpoint. The company paired these clinically promising data and regulatory progress with a roughly US$24.82 million follow-on equity raise and a finance leadership change,...
NYSE:HMN
NYSE:HMNInsurance

Is Horace Mann Educators (HMN) Price Justified After 5-Year 36.7% Share Return?

If you are wondering whether Horace Mann Educators at around US$44.92 still offers value, an important question is how its current price compares with what the business may be worth. The stock has returned 4.7% over the last 7 days, while the 1 year return sits at 21.7% and the 3 year return at 38.6%. A 0.6% decline year to date may suggest that expectations and risk perceptions are changing. Recent coverage has focused on Horace Mann Educators as an insurer serving the education community,...
NasdaqGM:SGMT
NasdaqGM:SGMTBiotechs

Why Sagimet Biosciences (SGMT) Is Up 7.7% After Denifanstat’s Phase 3 Acne Success And What's Next

Sagimet Biosciences recently reported that Ascletis Pharma’s Phase 3 trial of ASC40 (Denifanstat) for acne met all primary and secondary endpoints and was well-tolerated, with no serious adverse events observed. The results highlight fatty acid synthase (FASN) inhibition as a potentially new way to treat acne, with findings slated for presentation at upcoming medical congresses and in scientific publications. Next, we’ll examine how Denifanstat’s Phase 3 success in acne may influence Sagimet...